BAL0891

· SillaJen, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BAL0891, covering 2026-03-27 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]